Geopolitical jitters continue to weigh on the ASX healthcare sector, even as LTR Pharma advances its erectile dysfunction trial and Neuren’s partner pushes back on Europe’s rejection of its Rett syndrome drug.
Ovanti has terminated its proposed SPAC deal with Miluna Acquisition Corp as it pursues alternative pathways to list its US BNPL platform Flote on Nasdaq.
Tylah Tully looks at Golden Mile Resources and a raise to fast-track the exploration over a recently revealed Aurora gold prospect at its Pearl copper project in Arizona.
